Denosumab delays development of prostate cancer bone metastasis
Wednesday, November 16, 2011 - 05:30
in Health & Medicine
An international clinical trial has found that treatment with a drug that suppresses the normal breakdown of bone can delay the development of bone metastases in men with prostate cancer. The study, receiving Online First publication in The Lancet, is the first to successfully reduce bone metastasis in such patients and supports the importance of targeting the bone microenvironment to prevent prostate tumor spread.